Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huub Schellekens

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|December 7, 2007
The first biosimilar epoetin: but how similar is it?Huub Schellekens
Nature Biotechnology|November 6, 2004
How similar do 'biosimilars' need to be?Huub Schellekens
Biotechnology Annual Review|July 9, 2008
How to predict and prevent the immunogenicity of therapeutic proteinsHuub Schellekens
Clinical Therapeutics|April 9, 2008
The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiativeHuub Schellekens
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 10, 2004
Erythropoietic proteins and antibody-mediated pure red cell aplasia: a potential role for micellesHuub Schellekens
NDT Plus|May 23, 2009
Biosimilar therapeutics-what do we need to consider?Huub Schellekens
Current Medical Research and Opinion|September 19, 2003
Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasiaHuub Schellekens
Clinical Therapeutics|December 28, 2002
Immunogenicity of therapeutic proteins: clinical implications and future prospectsHuub Schellekens
Nature Biotechnology|February 11, 2014
A divided INN crowdHuub Schellekens
Neurology|November 12, 2003
The immunogenicity of biopharmaceuticalsHuub Schellekens
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Clinical Journal of the American Society of Nephrology : CJASN|December 7, 2007
The first biosimilar epoetin: but how similar is it?Huub Schellekens
Nature Biotechnology|November 6, 2004
How similar do 'biosimilars' need to be?Huub Schellekens
Biotechnology Annual Review|July 9, 2008
How to predict and prevent the immunogenicity of therapeutic proteinsHuub Schellekens
Clinical Therapeutics|April 9, 2008
The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiativeHuub Schellekens
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 10, 2004
Erythropoietic proteins and antibody-mediated pure red cell aplasia: a potential role for micellesHuub Schellekens
NDT Plus|May 23, 2009
Biosimilar therapeutics-what do we need to consider?Huub Schellekens
Current Medical Research and Opinion|September 19, 2003
Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasiaHuub Schellekens
Clinical Therapeutics|December 28, 2002
Immunogenicity of therapeutic proteins: clinical implications and future prospectsHuub Schellekens
Nature Biotechnology|February 11, 2014
A divided INN crowdHuub Schellekens
Neurology|November 12, 2003
The immunogenicity of biopharmaceuticalsHuub Schellekens
Pageof 13